Author:
Li Cong-Ran,Zhai Qian-Qian,Wang Xiu-Kun,Hu Xin-Xin,Li Guo-Qing,Zhang Wei-Xin,Pang Jing,Lu Xi,Yuan Hong,Gordeev Mikhail Fedorovich,Chen Le-Tian,Yang Xin-Yi,You Xue-Fu
Abstract
ABSTRACTMRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistantStaphylococcus aureus(MRSA), penicillin-resistantStreptococcus pneumoniae(PRSP), penicillin-intermediateS. pneumoniae(PISP), and vancomycin-resistant enterococci (VRE). In this study, thein vivoefficacy of orally administered MRX-I was evaluated using linezolid as a comparator. MRX-I showed the same or better efficacy than linezolid in both systemic and local infection models against the tested strains.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference7 articles.
1. Evaluation of antimicrobials in experimental animal infections;O'Reilly,2005
2. A simplified method of evaluating dose-effect experiments;Litchfield;J. Pharmacol. Exp. Ther.,1949
3. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model;Louie;Antimicrob. Agents Chemother.,2011
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献